Swiss Life Asset Management Ltd Lowers Stake in CVS Health Corporation $CVS

Key Points

• Swiss Life Asset Management cut its CVS Health stake by 36.5% in the fourth quarter, selling 213,343 shares and leaving it with 371,544 shares worth about $29.5 million.
• CVS reported stronger-than-expected Q1 results, with EPS of $2.57 versus $2.21 expected and revenue of $100.43 billion, while also raising its FY 2026 EPS guidance to 7.30–7.50.
• Analysts remain broadly positive on the stock: several firms raised price targets, and CVS currently has a Moderate Buy consensus with a target price of $96.12, even as insider Tilak Mandadi sold 69,551 shares in May.

Swiss Life Asset Management Ltd reduced its position in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 36.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 371,544 shares of the pharmacy operator's stock after selling 213,343 shares during the quarter. Swiss Life Asset Management Ltd's holdings in CVS Health were worth $29,486,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its position in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock worth $26,000 after purchasing an additional 281 shares during the last quarter. Corundum Trust Company INC acquired a new position in shares of CVS Health during the 3rd quarter worth about $29,000. Ares Financial Consulting LLC acquired a new position in shares of CVS Health during the 4th quarter worth about $29,000. Dogwood Wealth Management LLC raised its position in shares of CVS Health by 93.7% during the 4th quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator's stock worth $29,000 after purchasing an additional 179 shares during the last quarter. Finally, GoalVest Advisory LLC acquired a new position in shares of CVS Health during the 4th quarter worth about $32,000. Institutional investors and hedge funds own 80.66% of the company's stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: TD Cowen raised its price target on CVS Health to $110 from $105 and reiterated a buy rating, signaling confidence in further upside after the company’s earnings beat and improved outlook. TD Cowen adjusts price target on CVS Health to 110 from 105
• Positive Sentiment: Recent coverage highlights CVS as a potentially undervalued stock, pointing to strong Q1 revenue growth, higher EPS, and improving margins/medical benefit ratio as signs that fundamentals are strengthening. CVS Health: Still Cheap And Signs Of Improvement
• Positive Sentiment: Commentary from CNBC’s “Final Trades” and other market chatter suggests CVS remains a favored healthcare name among some investors, adding to the bullish tone. Nvidia, CVS Health, Vertiv and an energy stock on CNBC's Final Trades
• Neutral Sentiment: An executive stock sale by EVP Tilak Mandadi was disclosed, with 69,551 shares sold at an average price of $89.58. While insider selling can draw attention, the transaction appears more likely to be viewed as portfolio-related than a fundamental red flag. SEC Form 4 filing
• Neutral Sentiment: Additional articles this weekend argued CVS looks like a strong value stock and could benefit from broader healthcare policy trends, reinforcing the current bullish narrative but without new company-specific catalysts. Here's Why CVS Health (CVS) is a Strong Value Stock

Insider Transactions at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company's stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.85% of the company's stock.

CVS Health Stock Up 1.8%

Shares of NYSE CVS opened at $92.22 on Tuesday. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $92.77. The stock has a market cap of $117.67 billion, a PE ratio of 40.63, a P/E/G ratio of 0.88 and a beta of 0.60. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The company has a 50-day moving average of $77.43 and a 200 day moving average of $78.15.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to analysts' expectations of $94.99 billion. During the same quarter in the prior year, the company earned $2.25 EPS. CVS Health's revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 7.48 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health's dividend payout ratio is currently 117.18%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. The Goldman Sachs Group upped their price target on shares of CVS Health from $95.00 to $97.00 and gave the stock a "buy" rating in a research report on Thursday, February 12th. Barclays upped their price target on shares of CVS Health from $93.00 to $101.00 and gave the stock an "overweight" rating in a research report on Thursday. Sanford C. Bernstein upgraded shares of CVS Health from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $91.00 to $94.00 in a research report on Thursday, March 12th. Bank of America reduced their price target on shares of CVS Health from $100.00 to $95.00 and set a "buy" rating for the company in a research report on Tuesday, January 27th. Finally, HSBC upped their price target on shares of CVS Health from $83.00 to $85.00 and gave the stock a "hold" rating in a research report on Tuesday, May 5th. Twenty-two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $96.12.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.